CENTESSA PHARMACEUTICALS PLC - AMERICAN DEPOSITARY

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

24 Mar 2025 06:00:49 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

06 Mar 2025 15:14:40 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

28 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

08 Jan 2025 06:05:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

12 Nov 2024 06:00:15 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

26 Sep 2024 05:00:31 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

12 Sep 2024 21:34:37 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

11 Sep 2024 15:04:47 By Nasdaq GlobeNewswire

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

10 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

21 Aug 2024 07:00:45 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

13 Aug 2024 06:00:41 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

10 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

21 May 2024 07:45:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

13 May 2024 15:10:29 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23 Apr 2024 20:36:40 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

23 Apr 2024 15:17:37 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

22 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

28 Mar 2024 15:28:47 By Nasdaq GlobeNewswire